BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AviaraDx, Inc., Formerly Arcturus Bioscience, Inc., Announces Presentation At The 2006 Annual Biotechnology Industry Organization (BIO) Conference


4/12/2006 10:37:25 AM

CARLSBAD, Calif., April 12 /PRNewswire/ -- AviaraDx, Inc., formerly known as Arcturus Bioscience, Inc., announced today that Antonius Schuh, Ph.D., the Company's Chief Executive Officer, will present at the Annual BIO Conference on Wednesday, April 12, at 11:15 a.m. CST in the Room D of the McCormick Place South in Chicago.

Dr. Schuh will provide an update on the company's divesture of its products and assets related to the life science research market and AviaraDx, Inc.'s focus on its molecular cancer profiling technologies and business opportunities for tumor identification, patient prognosis and prediction of response to cancer therapies. He will address the company's development and commercial plans in the context of its commercial cancer diagnostic partnerships with Quest, LabCorp and Agendia.

About AviaraDx, Inc.

AviaraDx, Inc., formerly Arcturus Bioscience, Inc., is a leader in describing disease at the molecular level to enable molecular medicine and the development of proprietary technologies for diagnostic applications in oncology. These technologies include the Molecular Cancer Identification (MCID) technology which is based upon a set of clinically validated molecular signatures relating to 90% of the most common cancers, and the Breast Cancer Recurrence (BCR) technology, which is based upon a proprietary biomarker index for the prognosis of breast cancer recurrence risk and metastatic potential. Commercialization of the MCID Technology commenced with its licensing partners Quest Diagnostics, and Laboratory Corporation of America and Agendia BV for their Cancer of Unknown Primary (CUP) diagnostic service. Quest Diagnostics has also licensed the BCR technology for the development of a diagnostic service. AviaraDx technologies and intellectual properties position the company to address the multi-billion dollar market opportunities associated with the development and commercialization for additional cancer diagnostics and inventions to cost-effectively improve patient prognosis and response prediction in cancer therapy. AviaraDx has relocated its headquarters from Mountain View, California to Carlsbad, California. Please visit the AviaraDx website at https://www.aviaradx.com for more information.

CONTACT: Steve Zaniboni Chief Financial Officer +1-760-603-7700

AviaraDx, Inc.

CONTACT: Steve Zaniboni, Chief Financial Officer, of AviaraDx, Inc.,formerly Arcturus Bioscience, Inc., +1-760-603-7700



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES